EGFR and breast cancer: The SUMMIT trial provided clinical evidence (32% overall response rate at 8 weeks in breast cancer) that neratinib has actionability against several oncogenic HER2 mutations.42 Neratinib and lapatinib response significantly correlated with EGFR mutation (Table 1 and Fig. 4).